Retrospective Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Apr 21, 2017; 23(15): 2743-2749
Published online Apr 21, 2017. doi: 10.3748/wjg.v23.i15.2743
Table 1 Screenee characteristics in the cases with and without esophageal cancer n (%)
CharacteristicsTotal (n = 14790)Esophageal cancer(+) (n = 28)Esophageal cancer(-) (n = 14762)P value
Age (yr), median (range)61.0 (40-92)67.5 (55-76)61.0 (40-92)< 0.0011
Gender0.0022
Male9699 (65.6)26 (92.9)9673 (65.5)
Female5091 (34.4)2 (7.1)5089 (34.5)
Body mass index, median (range)23.3 (13.3-44.7)23.6 (17.6-31.3)23.3 (13.3-44.7)0.8851
Smoker0.1362
Current smoker1310 (12.9)4 (18.2)1306 (12.9)
Former smoker3921 (38.6)12 (54.5)3909 (38.5)
Non-smoker4936 (48.5)6 (27.3)4930 (48.6)
Alcohol0.1712
Current drinker7479 (73.6)20 (90.9)7459 (73.5)
Former drinker391 (3.8)0 (0.0)391 (3.9)
Non-drinker2297 (22.6)2 (9.1)2295 (22.6)
Table 2 Clinicopathologic findings of esophageal cancers detected in this study
Size (mm), median (range)12.5 (5-60)
Depth1
Tis/T1a/T1b12/15/5
Location
Ce/Ut/Mt/Lt/Mt-Lt/Ae0/1/20/8/2/1
Macroscopic type
0-IIc/0-IIc + IIa/0-I + IIb30/1/1
Histopathological type
SCC/ adenocarcinoma31/1
Treatment2, endoscopic treatment/ surgery/chemoradiotherapy/ radiation/unknown28/1/3/1/1
Lymph node metastasis
Positive/negative1/31
Distant metastasis
Positive/negative0/32
Table 3 Performance of 18-fluoro-2-deoxyglucose positron emission tomography for esophageal cancer screening
Esophageal cancer(+) (n = 28)Esophageal cancer(-) (n = 14762)PPV, NPV
FDG-PET positive (n = 51)150PPV 2.0%
(95%CI: 0.0-10.4)
FDG-PET negative (n = 14739)2714712NPV 99.8%
(95%CI: 99.7-99.9)
Sensitivity, specificitySensitivity 3.6%Specificity 99.7%
(95%CI: 0.1-18.3)(95%CI: 99.6-99.7)